Scrip
FDA reviewing safety of Sanofi-Aventis's Lantus insulin
02 July 2009
Malini Guha
Please Login to read the full article.
02 July 2009
Malini Guha
malini.guha@informa.com
The US
FDA is reviewing many sources of safety data for
Sanofi-Aventis's long-acting (once-daily) insulin analogue Lantus (insulin glargine) to better understand the risk, if any, for cancer. It is discussing with Sanofi-Aventis as to whether any additional studies evaluating the safety and efficacy...
Please Login to read the full article.
RELATED CONTENT
ANALYSIS
- Executive Briefing – Brazil emerges as a saviour for pharma
- Executive Briefing – Health technology assessment: a brief look at the EU
COMMENT
Other Informa Comment
FEATURES
- Anti-obesity drugs: an inventor's perspective
- Face-to-Face: Trophos - The French firm that hooked Actelion
EVENTS
01 January 1970
London, UK
01 January 1970
San Diego, US
01 January 1970
Providence, Rhode Island, and San Francisco, California
JOB OF THE WEEK
Promote your vacancy here
